Skip to content
DataLookout
Menu

NCT06879145

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)

At risk: Primary endpoint(s) modified, enrollment reduced 12%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 5 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Enrollment reduced: 840 → 740 participants
    • Interventions modified
    • Trial arms changed: 1 → 2
    • Secondary endpoints revised (8)
  2. Notable Eligibility criteria revisedv4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2025 to Apr 25, 2025
    • Site details revised
    v3
  4. Notable Start date: Mar 31, 2025 to May 2025v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase II: pCR evaluated by researchers
Timeframe: 3 months after the last subject underwent RC+PLD surgery.
Phase III: EFS assessed by BICR
Timeframe: 5 years after the first medication of the last subject.
Recommended Phase 3 Dose (RP3D)
Timeframe: 3 months after MIBC surgery.

Secondary (8)

ORR
DCR
pCR
EFS
DFS
Show 3 moreShow less
OS
Pathological downstaging (pDS)
AE

Arms and interventions

SHR-A2102 + Adebrelimab GroupExperimental

Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab.

Preoperative Chemotherapy GroupActive comparator

Preoperative chemotherapy with gemcitabine and cisplatin, and postoperative nivolumab treatment for patients with high-risk recurrence.

Drugs: SHR-A2102, Adebrelimab, Gemcitabine Hydrochloride for Injection, Cisplatin Injection, Nivolumab Injection

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China